Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

BACKGROUND: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukem...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kampa-Schittenhelm, Kerstin Maria, Heinrich, Michael Charles, Akmut, Figen, Döhner, Hartmut, Döhner, Konstanze, Schittenhelm, Marcus Matthias
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637582/
https://ncbi.nlm.nih.gov/pubmed/23497317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-12-19
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky